☰

Empresas y finanzas

Medidata Solutions Achieves Largest Revenue Quarter in Company History


    Medidata Solutions, a global leader in electronic data capture
    (EDC), management and reporting solutions, today announced the
    company's 25th quarter of consecutive growth and the largest revenue
    quarter in company history. Medidata made impressive gains with a 121
    percent year over year revenue growth. Ten new customers signed within
    the quarter to implement 16 trials spanning Phases I through IV, and
    10 existing customers signed follow-on contracts to continue using
    Medidata Rave(R) for multiple studies.

    Medidata continues to expand through direct wins from life science
    sponsors and its growing relationships with contract research
    organizations (CROs). Medidata's ASPire to Win(TM) partner program
    enables CROs to meet sponsor demand for Medidata Rave and offer the
    platform in-house by building and deploying studies with Rave
    certified resources.

    Other key accomplishments in Q1 include:

    -- Introduction of Rave 5.6 - Building on Medidata Rave's
    multiple language capabilities and ease-of-use, Medidata Rave
    5.6 offers broad EDC and CDMS functionality allowing sponsors
    to experience increased efficiencies and reduced risk in
    handling any size or phase study within a single, scalable
    system.

    -- Orion Corporation customer win - Finland-based pharmaceutical
    company standardized on Medidata Rave as its global EDC
    management and reporting solution, with the goal of managing
    all trials with Medidata Rave within the next few years.

    -- Fast Track partnership - Medidata entered into a multi-year
    agreement to integrate Fast Track's TrialSpace Designer(R)
    (TSD) study design software with Medidata Rave for faster
    trial start-up.

    -- ICON two-year milestone - At the second anniversary of
    Medidata's partnership with leading CRO ICON, the firms
    announced that Medidata Rave had been selected by 19 companies
    for 37 clinical trials across Phases I-IV, in a range of
    therapeutic areas.

    -- 18 percent staff increase - Medidata continued to expand in
    the U.S., Europe and Japan and added Dr. Hugh P. Levaux, Ph.D.
    as vice president of product strategy, to drive the overall
    definition and management of Medidata's product offerings.

    -- Global speaking engagements - Medidata executives delivered
    presentations at industry events in Q1, including the 5th
    Annual Phase IV Clinical Trials Conference, Clinical Trials
    Congress, DIA's 10th Annual Workshop in Japan for Clinical
    Data Management and International Symposium on Clinical
    Trials.

    "Our team's ability to listen and respond to the market with new
    product developments, form key partnerships and expand on
    relationships with CROs was critical to reaching the largest revenue
    quarter in our company's history," said Tarek Sherif, CEO of Medidata
    Solutions. "This milestone speaks to the momentum we have built with
    Medidata Rave, which, with broad CDMS capabilities, is viewed as the
    industry standard for EDC and clinical data management. As pleased as
    we are with earning the confidence of our new customers, we also value
    the continued roll-out of studies by customers who have signed
    enterprise-wide deployments. As sponsors and CROs continue to make
    investments in our technology, we look forward to announcing further
    achievements and expansion throughout the year."

    About Medidata Solutions Worldwide

    Medidata Solutions helps the world's leading pharmaceutical,
    biotechnology, medical device and research organizations maximize the
    value of their clinical research investments. Innovative process
    design, technology and services streamline clinical trials by
    providing early visibility to reliable clinical data - the lifeblood
    of every research organization. Working with companies and
    institutions both large and small, Medidata Solutions helps clinical
    researchers safely accelerate the process of bringing life-enhancing
    treatments to market - on six continents and in more than 80
    countries. Medidata Solutions brings significant value to its broad
    client base with deep clinical experience and expertise in more than
    20 therapeutic areas, projects in Phase I, II, III, IV, registries and
    surveillance, and studies with thousands of investigators and
    tens-of-thousands of subjects. For more information, please visit
    www.mdsol.com.